← Human Trials & Peer-Reviewed Studies
Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial.
Plain-language guide to PMID 28962046 (2017): double-blind randomized controlled trial of Glucagon.
Key Facts
- PMID
- 28962046
- Journal
- Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Roshanravan N et al. (10 authors)
- DOI
- 10.1055/s-0043-119089
What This Study Did, in Plain Language
What Was Tested
Researchers studied Glucagon in this randomized controlled trial publication.
The aim of this study was to evaluate the effects of sodium butyrate and high performance inulin supplementation simultaneously or singly on glycemic status, lipid profile, and glucagon-like peptide 1 level in adults with type 2 diabetes mellitus.
Why It Was Studied
The participants were randomly allocated, using randomized block procedure, to one of the four treatment groups (A, B, C, or D).
Group A received sodium butyrate capsules, group B received inulin supplement powder, group C was exposed to the concomitant use of inulin and sodium butyrate, and group D consumed placebo for 45 consecutive days.
Who Took Part
The age groups tagged for this paper are middle-aged adults, both men and women.
Sixty patients were recruited for the study.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.
Some participants received a placebo instead of Glucagon, giving a reference point.
Markers of glycemia, lipid profile, and glucagon-like peptide 1 were measured pre- and post-intervention.
What Was Measured
Topics PubMed links to this paper include Blood Glucose, Butyrates, Diabetes Mellitus, Type 2, Dietary Supplements, Glucagon-Like Peptide 1, Inulin and Lipids.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Glucagon.
The publication is from 2017 (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme), a journal based in Germany.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.